Genocea Biosciences Valuation
| GNCADelisted Stock | USD 0.0002 0.0001 100.00% |
Genocea Biosciences seems to be overvalued based on Macroaxis valuation methodology. Our model calculates the value of Genocea Biosciences from evaluating the firm fundamentals such as Return On Asset of -0.58, return on equity of -5.26, and Shares Outstanding of 58.78 M as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Genocea Biosciences' price fluctuation is very steady at this time. Calculation of the real value of Genocea Biosciences is based on 3 months time horizon. Increasing Genocea Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Genocea Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Genocea Stock. However, Genocea Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.0E-4 | Real 1.9E-4 | Hype 2.0E-4 |
The real value of Genocea Stock, also known as its intrinsic value, is the underlying worth of Genocea Biosciences Company, which is reflected in its stock price. It is based on Genocea Biosciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Genocea Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Genocea Biosciences helps investors to forecast how Genocea stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Genocea Biosciences more accurately as focusing exclusively on Genocea Biosciences' fundamentals will not take into account other important factors: Genocea Biosciences Total Value Analysis
Genocea Biosciences is currently forecasted to have valuation of (4.53 M) with market capitalization of 5.88 K, debt of 8.79 M, and cash on hands of 20.14 M. The negative valuation of Genocea Biosciences may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Genocea Biosciences fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(4.53 M) | 5.88 K | 8.79 M | 20.14 M |
Genocea Biosciences Investor Information
The company has price-to-book (P/B) ratio of 0.01. Some equities with similar Price to Book (P/B) outperform the market in the long run. Genocea Biosciences recorded a loss per share of 0.53. The entity last dividend was issued on the 22nd of May 30220. The firm had 1:8 split on the 22nd of May 2019. Based on the key indicators related to Genocea Biosciences' liquidity, profitability, solvency, and operating efficiency, Genocea Biosciences is not in a good financial situation at the moment. It has a very high risk of going through financial straits in March.Genocea Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Genocea Biosciences has an asset utilization ratio of 2.93 percent. This suggests that the Company is making $0.0293 for each dollar of assets. An increasing asset utilization means that Genocea Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.Genocea Biosciences Ownership Allocation
Genocea Biosciences has a total of 58.78 Million outstanding shares. Genocea Biosciences retains 6.22 (percent) of its outstanding shares held by insiders and 1.25 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Genocea Biosciences Profitability Analysis
The company reported the previous year's revenue of 1.64 M. Net Loss for the year was (33.2 M) with profit before overhead, payroll, taxes, and interest of 1.64 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Genocea Biosciences' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Genocea Biosciences and how it compares across the competition.
About Genocea Biosciences Valuation
The delisted stock valuation mechanism determines Genocea Biosciences' current worth on a weekly basis. Our valuation model uses a comparative analysis of Genocea Biosciences. We calculate exposure to Genocea Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Genocea Biosciences's related companies.Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Genocea Biosciences operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 74 people.
Genocea Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 68.6 M | |
| Retained Earnings | -407.9 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Genocea Stock
If you are still planning to invest in Genocea Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Genocea Biosciences' history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |